Share
Dr. Amoolya Singh
DELFI Diagnostics, Inc., a leader in developing accessible blood-based liquid biopsy tests for early cancer detection, has announced the appointment of Dr. Amoolya Singh as Chief Technology Officer.
In her new role, Dr. Singh will guide the company’s strategic technology initiatives, driving advancements in DELFI’s cutting-edge, AI-powered fragmentomics platform. This technology delivers groundbreaking genomic insights at a transformative cost, reinforcing DELFI’s mission to enhance early cancer detection and monitoring through innovative solutions.
Dr. Singh joins DELFI Diagnostics with over 20 years of experience at the intersection of biotechnology and computational science. Her leadership track record includes serving as Senior Vice President of Data Science and Chief Scientific Officer at Grail, leading Discovery Technologies at Calico (Alphabet's drug discovery company), and serving as Vice President of R&D at Amyris.
Dr. Singh earned her Ph.D. in Computational Biology and M.S. in Computer Science from the University of California, Berkeley, and her B.S. in Biology and Computer Science from Carnegie Mellon University. She completed prestigious postdoctoral fellowships at the European Molecular Biology Lab in Heidelberg, Germany, and Emory University as part of the Computational and Life Sciences fellowship program.
With her extensive expertise in biotechnology, computational biology, and technology leadership, Dr. Singh will play a pivotal role in advancing DELFI’s mission to make early cancer detection more accessible and impactful.
Related posts
